Delcath Systems (DCTH) 10-K 18 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 18, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	872,912
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 11,848,790
Entity Common Stock, Shares Outstanding		24,043,491
Document Fiscal Year Focus	2,015
Trading Symbol	DCTH
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 12,607	$ 20,469
Accounts receivables, net	277	174
Inventories	757	349
Prepaid expenses and other current assets	960	974
Total current assets	14,601	21,966
Property, plant and equipment, net	1,132	1,798
Total assets	15,733	23,764
Current liabilities
Accounts payable	284	748
Accrued expenses	2,243	3,603
Warrant liability	3,785	225
Total current liabilities	6,312	4,576
Other non-current liabilities	820	1,043
Total liabilities	7,132	5,619
Commitments and contingencies	0	0
Stockholders' equity
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively	0	0
Common stock, $.01 par value; 170,000,000 shares authorized; 22,341,574 and 9,740,394 shares issued and 21,763,817 and 9,708,841 shares outstanding at December 31, 2015 and December 31, 2014, respectively	223	97
Additional paid-in capital	269,654	264,592
Accumulated deficit	(261,217)	(246,513)
Treasury stock, at cost; 1,757 shares at December 31, 2015 and December 31, 2014, respectively	(51)	(51)
Accumulated other comprehensive income (loss)	(8)	20
Total stockholders' equity	8,601	18,145
Total liabilities and stockholders' equity	$ 15,733	$ 23,764

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	22,341,574	9,740,394
Common stock, shares outstanding (in shares)	21,763,817	9,708,841
Treasury stock, at cost (in shares)	1,757	1,757

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Product revenue		$ 1,747	$ 1,069	$ 490
Other revenues				300
Total revenue		1,747	1,069	790
Cost of goods sold		(462)	(291)	(464)
Gross profit		1,285	778	326
Operating expenses:
Selling, general and administrative expenses		10,009	15,783	20,657
Research and development costs		6,486	4,299	12,688
Total operating expenses		16,495	20,082	33,345
Operating loss		(15,210)	(19,304)	(33,019)
Derivative instrument income		564	1,942	2,756
Interest income		9	5	20
Other (expense) income and interest expense		(67)	(24)	(81)
Net loss		$ (14,704)	$ (17,381)	$ (30,324)
Common share data:
Basic loss per share	[1]	$ (0.91)	$ (1.84)	$ (4.81)
Diluted loss per share	[1]	$ (0.91)	$ (1.84)	$ (5.10)
Weighted average number of basic shares outstanding	[1]	16,161,687	9,452,050	6,300,614
Weighted average number of diluted shares outstanding	[1]	16,161,687	9,452,050	6,569,011
Other comprehensive income (loss):
Foreign currency translation adjustments		$ (28)	$ (76)	$ 59
Comprehensive Loss		$ (14,732)	$ (17,457)	$ (30,265)
[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)	12 Months Ended
	Dec. 31, 2015
Income Statement [Abstract]
Reverse stock split ratio description	one-for-sixteen (1:16)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	In Treasury [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]
Balance at Dec. 31, 2012	$ 20,009	$ 48	$ (51)	$ 218,783	$ (198,808)	$ 37
Balance (in shares) at Dec. 31, 2012		4,811,588	(1,757)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	174	$ 0	$ 0	174	0	0
Compensation expense for issuance of restricted stock	117	$ 0	$ 0	117	0	0
Compensation expense for issuance of restricted stock (in shares)		8,604	0
Sale of common stock, net of expenses	$ 41,460	$ 36	$ 0	41,424	0	0
Sale of common stock, net of expenses (in shares)	0	3,570,061	0
Exercise of warrants	$ 243	$ 0	$ 0	243	0	0
Exercise of warrants (in shares)		12,669	0
Fair value of warrants exercised	218	$ 0	$ 0	218	0	0
Fair value of warrants issued classified as liability	(1,857)	0	0	(1,857)	0	0
Net loss	(30,324)	0	0	0	(30,324)	0
Foreign currency translation	59	0	0	0	0	59
Balance at Dec. 31, 2013	30,099	$ 84	$ (51)	259,102	(229,132)	96
Balance (in shares) at Dec. 31, 2013		8,402,922	(1,757)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	391	$ 0	$ 0	391	0	0
Compensation expense for issuance of restricted stock	100	$ 0	$ 0	100	0	0
Compensation expense for issuance of restricted stock (in shares)		28,256	0
Sale of common stock, net of expenses	4,743	$ 13	$ 0	4,730	0	0
Sale of common stock, net of expenses (in shares)		1,260,079	0
Exercise of warrants	126	$ 0	$ 0	126	0	0
Exercise of warrants (in shares)		49,137	0
Fair value of warrants exercised	143	$ 0	$ 0	143	0	0
Net loss	(17,381)	0	0	0	(17,381)	0
Foreign currency translation	(76)	0	0	0	0	(76)
Balance at Dec. 31, 2014	18,145	$ 97	$ (51)	264,592	(246,513)	20
Balance (in shares) at Dec. 31, 2014		9,740,394	(1,757)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	349	$ 0	$ 0	349	0	0
Compensation expense for issuance of restricted stock	308	$ 6	$ 0	302	0	0
Compensation expense for issuance of restricted stock (in shares)		575,862	0
Sale of common stock, net of expenses	8,479	$ 118	$ 0	8,361	0	0
Sale of common stock, net of expenses (in shares)		11,810,000	0
Exercise of warrants	176	$ 2	$ 0	174	0	0
Exercise of warrants (in shares)		215,318	0
Fair value of warrants exercised	123	$ 0	$ 0	123	0	0
Fair value of warrants issued classified as liability	(4,247)	0	0	(4,247)	0	0
Net loss	(14,704)	0	0	0	(14,704)	0
Foreign currency translation	(28)	0	0	0	0	(28)
Balance at Dec. 31, 2015	$ 8,601	$ 223	$ (51)	$ 269,654	$ (261,217)	$ (8)
Balance (in shares) at Dec. 31, 2015		22,341,574	(1,757)

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Stockholders Equity [Abstract]
Common stock issued, par value	$ 0.01	$ 0.01	$ 0.01

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (14,704)	$ (17,381)	$ (30,324)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	349	391	174
Restricted stock compensation expense	308	100	117
Depreciation expense	617	958	1,126
Provision or inventory obsolescence	0	118	0
Loss on disposal of equipment	15	282	5
Warrant liability fair value adjustment	(564)	(1,942)	(2,756)
Non-cash interest income	(1)	0	(1)
Changes in assets and liabilities:
(Increase) decrease in prepaid expenses and other assets	9	718	(235)
(Increase) decrease in accounts receivable	(52)	161	(211)
(Increase) decrease in inventories	(420)	237	391
(Decrease) increase in accounts payable and accrued expenses	(1,757)	132	(2,445)
Increase (decrease) in other non-current liabilities	(220)	674	57
Net cash used in operating activities	(16,420)	(15,552)	(34,102)
Cash flows from investing activities:
Purchase of property, plant and equipment	(170)	(44)	(142)
Proceeds from sales of property, plant and equipment	180	37	0
Net cash provided by (used in) investing activities	10	(7)	(142)
Cash flows from financing activities:
Net proceeds from sale of stock and exercise of warrants	8,655	4,869	41,702
Net cash provided by financing activities	8,655	4,869	41,702
Foreign currency effects on cash and cash equivalents	(107)	(90)	65
Net increase (decrease) in cash and cash equivalents	(7,862)	(10,780)	7,523
Cash and cash equivalents:
Beginning of period	20,469	31,249	23,726
End of period	12,607	20,469	31,249
Supplemental non-cash activities:
Fair value of warrants issued	4,247	0	1,857
Fair value of warrants exercised	$ 123	$ 143	$ 218

Description of Business and Liq

Description of Business and Liquidity	12 Months Ended
	Dec. 31, 2015
Description Of Business And Liquidity [Abstract]
Description of Business and Liquidity	(1) Description of Business and Liquidity Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. We are a specialty pharmaceutical and medical device company developing our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT ® Our primary focus is on the execution of our clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has accumulated deficit of $261.2 million at December 31, 2015. As shown in the accompanying financial statements during year ended December 31, 2015, the Company incurred net losses of $14.7 million and used $16.4 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through the third quarter of 2016, but anticipates that additional working capital will be required to continue operations. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing or sales experience; and dependence on key personnel.

Basis of Consolidated Financial

Basis of Consolidated Financial Statement Presentation	12 Months Ended
	Dec. 31, 2015
Basis Of Condensed Consolidated Financial Statement Presentation [Abstract]
Basis of Consolidated Financial Statement Presentation	(2) Basis of Consolidated Financial Statement Presentation The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company’s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies Use of Estimates The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates. Cash Equivalents and Concentrations of Credit Risk The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution. Accounts Receivable Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified. Inventories Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2015 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly. Property, Plant and Equipment Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. Fair Value Measurements The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). · Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. · Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. · Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Revenue Recognition Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. Selling, General and Administrative Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred. Research and Development Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred. Stock Based Compensation The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant. The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2015, 2014, and 2013 are as follows: (in thousands, except share data) 2015 2014 2013 Net loss – basic $ (14,704 ) $ (17,381 ) $ (30,324 ) Adjust for gain on warrant derivative liability — — (1,835 ) Net loss - diluted (14,704 ) (17,381 ) (32,159 ) Net loss per share – basic (0.91 ) (1.84 ) (4.81 ) Weighted average shares outstanding – basic 16,161,687 9,452,050 6,300,614 Potentially dilutive warrant exercises — — 268,397 Weighted average shares outstanding – diluted 16,161,687 9,452,050 6,569,011 Net loss per share – diluted (0.91 ) (1.84 ) (5.10 ) For the years ended December 31, 2015, 2014 and 2013, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive. Shares excluded from the computation of diluted EPS: 2015 2014 2013 Stock options 756,051 281,735 252,158 Unvested restricted shares 576,000 29,799 20,347 Warrants 18,059,000 850,138 589,500 Total 19,391,051 1,161,672 862,005 Segment Information The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments. Foreign Currency and Currency Translation Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations. The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income. Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluation the impact of ASU 2014-09 on its consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company expects to adopt this guidance when effective, and does not anticipate that this guidance will materially impact its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the accounting transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. As of December 31, 2015, the company is not early adopting ASU 2015-17. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact of the pending adoption of ASU 2016-02 on its consolidated financial statements.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	(4) Inventories Inventories consist of: (in thousands) December 31, 2015 December 31, 2014 Raw materials $ 360 $ 203 Work-in-process 251 63 Finished goods 146 83 Total Inventory $ 757 $ 349

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	(5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include the following: (in thousands) December 31, 2015 December 31, 2014 Insurance premiums $ 625 $ 591 Kits for clinical use 162 161 Other 173 222 Total prepaid expenses and other current assets $ 960 $ 974 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2015 and 2014.

Property, Plant, and Equipment

Property, Plant, and Equipment	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Property, Plant, and Equipment	(6) Property, Plant, and Equipment Property, plant, and equipment consists of: (in thousands) December 31, 2015 December 31, 2014 Buildings and land $ 556 $ 1,629 Enterprise hardware and software 1,520 1,573 Leaseholds 1,305 361 Equipment 902 1,380 Furniture 355 603 Property, plant and equipment, gross 4,638 5,546 Accumulated depreciation (3,506 ) (3,748 ) Property, plant and equipment, net $ 1,132 $ 1,798 Depreciation expense for the years ended December 31, 2015, 2014, and 2013 was $0.6 million, $1.0 million, and $1.1 million, respectively.

Current Accrued Expenses

Current Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Current Accrued Expenses	(7) Current Accrued Expenses Current accrued expenses include the following: (in thousands) December 31, 2015 December 31, 2014 Compensation, excluding taxes $ 692 $ 2,187 Professional fees 391 341 Short-term portion of lease restructuring 220 239 Clinical trial expenses 219 124 Other 721 712 Total accrued expenses $ 2,243 $ 3,603 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2015 and 2014.

Restructuring Expenses

Restructuring Expenses	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Restructuring Expenses	(8) Restructuring Expenses Beginning in 2013, the Company implemented several workforce restructurings to reduce operating costs, better focus its organizational structure, increase efficiency and concentrate financial resources on its clinical development program and European commercialization activity. This resulted in a total reduction in the Company’s workforce by 59 employees. As a result of termination benefits provided to these employees the Company has incurred a total restructuring charge of approximately $5.5 million for employee related expenses. At December 31, 2015, the remaining restructuring reserve of approximately $0.1 million is included in Accrued expenses on the condensed consolidated balance sheets. In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of December 31, 2015, the total remaining lease restructuring liability for its leased office space was approximately $1.0 million, of which approximately $0.2 million and $0.8 million were included in Accrued expenses and Other non-current liabilities on the condensed consolidated balance sheets, respectively. The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2015: (in thousands) Employee Costs Lease Liability Total Liability Reserve balance at December 31, 2014 $ 824 $ 1,282 2,106 Charges 403 — 403 Payments/Utilizations (1,156 ) (243 ) (1,399 ) Reserve balance at December 31, 2015 $ 71 $ 1,039 1,110

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value	(9) Assets and Liabilities Measured at Fair Value Derivative Financial Instruments As disclosed in Note 10, the Company allocated part of the proceeds of public offerings in 2012, 2013 and 2015 to the warrants issued in connection with those transactions. The warrants have been classified as liabilities and accounted for as a derivative instrument in accordance with ASC 815 due to certain provisions within the warrant agreements. The valuation of the warrants (“the Warrants”) is determined using option pricing models. These models use inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy. In July 2015, the Company completed the sale of 9.4 million Units consisting of 9.4 million shares of its common stock, Series A Warrants to purchase up to 7.0 million common shares (“July 2015 Series A Warrants”) and Series B Warrants to purchase Units consisting of up to 9.4 million common shares (“July 2015 Series B Warrants”) and 7.0 million July 2015 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the July 2015 Series A and Series B Warrants. The exercise price of both series of warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2015, the July 2015 Series A Warrants were exercisable at $0.87 with approximately 7.0 million warrants outstanding and the July 2015 Series B Warrants were exercisable at $0.75 with approximately 9.4 million outstanding. The July 2015 Series A Warrants have a five-year term. July 2015 Series B Warrants expired January 29, 2016. There were no July 2015 Series A or Series B Warrants exercised during the year ended December 31, 2015. In February 2015, the Company completed the sale of 2.5 million shares of its common stock and the issuance of warrants to purchase 1.1 million common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2015, the February 2015 Warrants were exercisable at $0.74 per share with approximately 1.1 million warrants outstanding. The February 2015 Warrants have a five-year term. There were no February 2015 Warrants exercised during the year ended December 31, 2015. In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase approximately 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2015, the 2013 Warrants were exercisable at $7.04 per share with approximately 0.6 million warrants outstanding. The 2013 Warrants have a five-year term. There were no 2013 Warrants exercised during the year ended December 31, 2015. In May 2012, the Company completed the sale of 1.0 million shares of its common stock and the issuance of warrants to purchase 0.3 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. The exercise price was subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants was subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s February 2015 sale of common stock and warrants. During the year ended December 31, 2015, 0.2 million 2012 Warrants were exercised for net proceeds of approximately $0.2 million. The 2012 Warrants had a three-year term which expired on May 31, 2015. The remaining liability was credited to Derivative instrument income. For the year ended December 31, 2015, the Company recorded pre-tax derivative instrument income of $0.6 million. The resulting derivative instrument liabilities totaled $3.8 million at December 31, 2015. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2015 was determined by using option pricing models assuming the following: Series A 2015 Warrants Series B 2015 Warrants February 2015 Warrants October 2013 Warrants Expected volatility 92.13% 94.03% 92.91% 97.76% Risk free interest rates 1.65% 0.14% 1.54% 1.25% Expected life (in years) 4.56 0.08 4.13 2.83 Money Market Funds The Company has determined that the inputs associated with the fair value determination are based on quoted prices (unadjusted) and as a result the investments are classified within Level 1 of the fair value hierarchy. The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and 2014, aggregated by the level in the fair value hierarchy within which those measurements fall. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Level 2 Level 3 Balance at December 31 (in thousands) 2015 2014 2015 2014 2015 2014 2015 2014 Assets Money market funds (included in Cash and Cash Equivalents) $ 1,943 $ 1,943 $ — $ — $ — $ — $ 1,943 $ 1,943 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 3,785 $ 225 $ 3,785 $ 225 Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at January 1, 2013 $ 3,427 Total change in the liability included in earnings (2,756 ) Fair value of warrants issued 1,857 Fair value of warrants exercised (218 ) Balance at December 31, 2013 2,310 Total change in the liability included in earnings (1,942 ) Fair value of warrants exercised (143 ) Balance at December 31, 2014 225 Total change in the liability included in earnings (564 ) Fair value of warrants issued 4,247 Fair value of warrants exercised (123 ) Balance at December 31, 2015 $ 3,785

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity Reverse Stock Split On February 24, 2014, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock. The reverse stock split became effective on April 8, 2014 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the close of the NASDAQ market on April 8, 2014 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the number of common shares authorized or the par value per share of Delcath common stock, which remain 170,000,000 and $0.01, respectively. All current and prior period amounts related to shares, share prices and earnings per share, presented in these Consolidated Financial Statements and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split. Stock Issuances In July 2015, the Company completed the sale of 9.4 million Units consisting of 9.4 million shares of its common stock, Series A Warrants to purchase up to 7.0 million common shares (“July 2015 Series A Warrants”) and Series B Warrants to purchase Units consisting of up to 9.4 million common shares (“July 2015 Series B Warrants”) and 7.0 million July 2015 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the July 2015 Series A and Series B Warrants. The exercise price of both series of warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2015, the July 2015 Series A Warrants were exercisable at $0.87 with approximately 7.0 million warrants outstanding and the July 2015 Series B Warrants were exercisable at $0.75 with approximately 9.4 million outstanding. The July 2015 Series A Warrants have a five-year term. July 2015 Series B Warrants expired January 29, 2016. In February 2015, the Company completed the sale of 2.5 million shares of its common stock and the issuance of warrants to purchase 1.1 million common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2015, the February 2015 Warrants were exercisable at $0.74 per share with approximately 1.1 million warrants outstanding. The February 2015 Warrants have a five-year term. In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2015, the 2013 Warrants were exercisable at $7.04 per share with approximately 0.6 million warrants outstanding. The 2013 Warrants have a five-year term. As of December 31, 2015, the Company had two active registration statements. Pursuant to SEC regulations, so long as the Company’s public float remains below $75 million, we cannot sell securities from the shelf registration statement which represent more than one third of the market value of our non-affiliated public float during any 12-month period. In October 2015, the Company filed a registration statement on Form S-3 with the SEC, which was declared effective on October 20, 2015 and allows the Company to offer and sell, from time to time in one or more offerings, up to $77.4 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. This registration statement replaces the shelf registration filed in October 2012. As of December 31, 2015, the Company had approximately $77.4 million available subject to market conditions and certain SEC limitations discussed above. At-the-Market (“ATM”) Program In March 2013, the Company entered into a new agreement with Cowen to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 1.0 million shares of its common stock under this ATM program for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. During the year ended December 31, 2015 the Company sold an additional 1.0 million shares of its common stock under this ATM program for proceeds of approximately $4.8 million, with net cash proceeds after related expenses of approximately $4.7 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of its products, obtaining regulatory approvals, funding of clinical trials, capital expenditures and working capital. As of December 31, 2015, the Company has approximately $39.9 million available under the program subject to market conditions and certain SEC limitations. Stock Incentive Plans The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 187,500, and 1,506,250 shares, respectively, were reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In June 2015, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 1,100,000 shares, from 406,250 to 1,506,250 shares, upon a favorable vote by the Company’s stockholders. A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. The Plans are administered by the Compensation and Stock Option Committee of the board of directors which determines the individuals to whom awards shall be granted as well as the type, terms and conditions of each award, the option price and the duration of each award. As of December 31, 2015, there were 185,450 shares available to grant under the 2009 Stock Incentive Plan. Stock option activity for 2015, 2014, and 2013 is as follows: Stock Option Activity under the Plans Stock Options Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2012 299,242 $19.68 - 248.64 $ 76.66 6.88 Granted 130,328 4.80 - 34.08 17.41 Forfeited (160,538 ) 19.68 - 29.92 24.47 Expired (16,874 ) 6.08 - 197.44 63.50 Outstanding at December 31, 2013 252,158 $4.80 - 248.64 $ 57.90 7.36 Granted 165,000 1.24 - 2.42 1.78 Forfeited (89,757 ) 4.80 - 248.64 67.58 Expired (45,666 ) 4.80 - 110.40 47.54 Outstanding at December 31, 2014 281,735 $1.24 - $245.12 $ 23.63 8.83 Granted 524,250 1.19 1.19 Forfeited (49,934 ) 1.19 - 169.60 30.01 Outstanding at December 31, 2015 756,051 $1.24 - $245.12 $ 7.65 8.95 Exercisable at December 31, 2015 188,249 $1.24 - $245.12 $ 26.45 7.67 For the years ended December 31, 2015, 2014 and 2013 the Company recognized compensation expense related to stock option grants of approximately $0.3 million, $0.4 million and $0.2 million, respectively. The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the years ended December 31, 2015, 2014 and 2013: Year ended December 31, 2015 2014 2013 Weighted average risk-free interest rates 1.82 % 1.53 % 1.30 % Weighted average expected volatility 97.70 % 96.68 % 92.31 % Expected volatility 97.70 % 95.47% - 98.14% 86.16% - 97.21% Dividend yield — — — Weighted average expected option term (in years) 5.15 4.50 5.66 Weighted average grant date fair value $ 0.89 $ 1.78 $ 17.41 No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during 2015, 2014, 2013 and the second half of 2012 is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized because the Company did not have sufficient historical experience from which to estimate the period. A summary of the Company’s non-vested options to purchase shares as of December 31, 2015 and changes during the year ended December 31, 2015 and December 31, 2014 are presented below: Non-Vested Options Number of Options Weighted Average Exercise Price Non-vested at January 1, 2014 118,610 $ 20.76 Granted 165,000 1.78 Vested (46,737 ) 26.35 Forfeited (10,772 ) 35.92 Non-vested at December 31, 2014 226,101 $ 5.03 Granted 524,250 1.19 Vested (159,901 ) 5.36 Forfeited (22,648 ) 4.38 Non-vested at December 31, 2015 567,802 $ 1.42 Additional compensation expense of $0.2 million, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 1.14 years. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2015 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $0.50 as of December 31, 2015, which would have been received by the option holders had those option holders exercised their options as of that date. A summary of the Company’s restricted stock activity as of December 31, 2015 and changes during the year ended December 31, 2015 and December 31, 2014 are presented below: Restricted Stock Activity Number of Shares Weighted Average Grant Date Fair Value Non-vested at January 1, 2014 20,347 $ 16.84 Granted 62,504 2.60 Vested (18,815 ) 13.60 Forfeited (34,237 ) 3.40 Non-vested at December 31, 2014 29,799 $ 4.46 Granted 576,000 1.19 Vested (29,666 ) 4.38 Forfeited (133 ) 21.58 Non-vested at December 31, 2015 576,000 $ 1.19 For the years ended December 31, 2015, 2014 and 2013 the Company recognized compensation expense related to restricted stock grants of approximately $0.3 million, $0.1 million and $0.1 million, respectively. Additional compensation expense of $0.4 million relating to the unvested portion of restricted stock granted is expected to be recognized over a remaining average period of 1.45 years. Warrants The Company issued warrants as part of its offerings in 2012, 2013, and 2015. A summary of warrant activity is as follows: Warrants Exercise per Share Weighted Average Exercise Price Weighted Average Remaining Life (Years) Outstanding at January 1, 2013 352,664 $ 19.20 $ 19.20 2.24 Issued 589,500 7.04 Exercised (12,669 ) 19.20 Expired — — Outstanding at December 31, 2013 929,495 $2.56 – 7.04 $ 5.40 3.51 Issued — — Exercised (49,139 ) 2.56 Expired (30,218 ) 2.56 Outstanding at December 31, 2014 850,138 $1.75 – 7.04 $ 5.42 2.78 Issued 17,469,500 0.80 Exercised (215,318 ) 0.82 Expired (45,320 ) 0.82 Outstanding at December 31, 2015 18,059,000 $0.74 – 7.04 $ 1.00 2.16

Loan and Security Agreement

Loan and Security Agreement	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Loan and Security Agreement	(11) Loan and Security Agreement In April 2012, the Company entered into a four-year Loan and Security Agreement (the “Credit Agreement“) with Silicon Valley Bank (“SVB”), as lender. The Credit Agreement consists of a revolving credit facility in an amount equal to the lesser of $20,000,000 and the Company’s Borrowing Base (as defined in the Credit Agreement). In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB. As of December 31, 2015, the Company cannot access the credit facility due to the restrictions listed above.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments	(12) Commitments Operating Leases In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space at 810 Seventh Avenue, New York, NY with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010. In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Initial Lease and the Lease Amendment provide for annual rent of $961,000 in 2012, $970,000 in 2013, $996,000 in 2014 and 2015, $1.0 million in 2016, and $1.1 million in 2017-2020. As discussed in Note 8, the Company has sub-leased this office space. In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August 2, 2011. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The annual lease amounts, which escalate annually, are as follows (USD conversions are based on the December 31, 2015 conversion rate): Year 1 – €106,051 ($115,458), Year 2 – €134,974 ($146,946), Year 3 – €159,077 ($173,187) and Years 4 and 5 – €183,179 ($199,427). Annual lease amounts in years 6 through 10 are subject to adjustment based upon the percentage increase in the consumer price index as published by the Ireland Central Statistics Office. Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath. In June 2012, the Company entered into an agreement to lease 18,000 square feet at Suites 2 and 3 Country Club Road, Queensbury, NY for a three year period. This amends the initial lease at 2 Country Club Road, which commenced in November 2010. The location housed a portion of the Company’s research and manufacturing operations. The lease provided for annual base rent of $216,000, as well as the payment of customary building operating expenses and real estate taxes. This lease expired in June 2015 and Delcath no longer occupies the premises. In September 2014, the Company entered into a license agreement to lease approximately 5,818 square feet of office space at 1301 Avenue of the Americas, New York, NY. The term began on October 1, 2014 and is effective through May 20, 2016. The agreement provides for total annual base rent of $200,000. In October 2014, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on November 1, 2014 and was effective for a one year period. The Company renewed this lease for one additional year. The renewal provides for total annual base rent of $47,277 and will expire October 31, 2016. Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2015 are as follows: (in thousands) Future Payment 2016 $ 505 2017 455 2018 460 2019 442 2020 435 2021 175 $ 2,472 Rent expense totaled approximately $0.4 million, $2.3 million and $1.5 million, for the years ended December 31, 2015, 2014 and 2013, respectively. Of the $2.3 million in expense for 2014, approximately $1.3 million is related to restructuring charges discussed in Note 8. Letters of Credit Under the terms of the lease agreement for office space at 810 Seventh Avenue, New York, NY, the Company is required to maintain a letter of credit in the amount of $881,297 which will expire in February 2017 if not renewed by the Company. Under the terms of the license agreement for office space at 1301 Avenue of the Americas, New York, NY, the Company is required to maintain a letter of credit in the amount of $200,000 which will expire with the sublease in May, 2016.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes There is no income tax provision for the years ended December 31, 2015, 2014 and 2013. Income before income taxes consists of: Year Ended December 31, (in thousands) 2015 2014 2013 Domestic $ (11,276 ) $ (12,950 ) $ (19,142 ) Foreign (3,428 ) (4,431 ) (11,182 ) Income before taxes $ (14,704 ) $ (17,381 ) $ (30,324 ) The provision for income taxes differs from the amount computed by applying the statutory rate as follows: Year Ended December 31, (in thousands) 2015 2014 2013 Income taxes using U.S federal statutory rate $ (4,999 ) $ (5,926 ) $ (10,309 ) Amortization of gain on IP migration 767 767 781 State income taxes, net of federal benefit 380 2,215 (1,390 ) Foreign rate differential 920 1,069 2,761 Valuation allowance 2,649 886 7,683 Derivative charge (192 ) (660 ) (937 ) Stock option exercises and cancellations 674 1,748 1,589 Research and development costs (199 ) (125 ) (1,090 ) Other — 26 912 $ — $ — $ — Significant components of the Company’s deferred tax assets are as follows: (in thousands) December 31, 2015 December 31, 2014 Deferred tax assets: Employee compensation accruals $ 1,279 $ 1,866 Accrued liabilities 633 1,356 Research tax credits 3,796 3,597 Other 66 45 Net operating losses 77,906 74,359 Total deferred tax assets 83,680 81,223 Deferred tax liabilities: Total deferred tax liabilities — — Valuation allowance 83,680 81,223 Net deferred tax assets $ — $ — As of December 31, 2015 and December 31, 2014, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $184.5 million and $171.6 million, respectively. A portion of the federal amount, $8.6 million, is subject to an annual limitation of approximately $123,000 as a result of a change in the Company’s ownership through May 2003, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitation, approximately $175.9 million is available to offset future federal taxable income which will expire between 2018 and 2035. In addition, the Company’s state net operating losses are also subject to annual limitations that generally follow the federal Section 382 provisions, adjusted for each state’s respective income apportionment percentages. As of December 31, 2015 and December 31, 2014, the Company had net operating loss carryforwards for state and city income tax purposes between approximately $27.3 million and $109.7 million and between approximately $276.3 million and $110.5 million, respectively, which expire through 2035. As of December 31, 2015 and December 31, 2014, the Company had a net operating loss carryforward for foreign income tax purposes of $22.1 million and $21.8 million, respectively, which have indefinite carryforward periods. As of December 31, 2015 and December 31, 2014, the Company had federal research and development tax credit carryforwards of approximately $3.8 million and $3.6 million, respectively, which expire through 2035. The Company has a tax benefit of approximately $1.0 million related to the exercise of non-qualified stock options. Pursuant to ASC 718, the benefit will be recognized and recorded to additional paid-in capital when the benefit is realized through the reduction of taxes payable. Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company’s valuation allowance increased by approximately $2.6 million, $0.9 million, and $7.7 million in 2015, 2014, and 2013, respectively. The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10. The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company is currently under examination by the Internal Revenue Service for the period ending December 31, 2013. The examination commenced in the third quarter of 2015 and as of December 31, 2015, there have been no adjustments proposed. The Company's total amount of unrecognized tax benefits could increase within the next twelve months as a result of the exam. However, the effect of the outcome cannot be reasonably estimated as the exam is presently in its initial stages and the IRS is in the process of issuing information document requests (IDR's) to obtain information and documents substantiating positions reflected on the tax return under examination. The Company has not been audited by any state tax authorities in connection with income taxes. The Company has not been audited by international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	(14) Quarterly Financial Data (Unaudited) Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2015 and 2014. 2015 Quarters Ended (in thousands except per share amounts) March 31 June 30 September December 31 Operating loss $ (3,708 ) (3,623 ) (3,650 ) (4,229 ) Change in fair value of warrant liability, net 209 (48 ) 1,253 (850 ) Net loss (3,488 ) (3,699 ) (2,422 ) (5,095 ) Basic and diluted loss per share (0.32 ) (0.30 ) (0.12 ) (0.23 ) 2014 Quarters Ended (in thousands except per share amounts) March 31 June 30 September December 31 Operating loss $ (5,059 ) (5,904 ) (5,054 ) (3,285 ) Change in fair value of warrant liability, net (205 ) 1,297 519 330 Net loss (5,278 ) (4,600 ) (4,558 ) (2,945 ) Basic loss per share (0.57 ) (0.49 ) (0.48 ) (0.31 ) Diluted loss per share (0.57 ) (0.52 ) (0.48 ) (0.31 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	(15) Subsequent Events NASDAQ Notification Letter On February 9, 2016, The NASDAQ Stock Market (“NASDAQ”) granted Delcath Systems, Inc. (the “Company”) an additional 180 calendar days, or until August 8, 2016, to regain compliance with the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Rule”). On August 11, 2015, the Company received a notification letter (the “Notice”) from NASDAQ advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to the Minimum Bid Price Rule. The Company was provided 180 calendar days, or until February 8, 2016, to regain compliance with the Minimum Bid Price Rule. The Company was unable to regain compliance with the Minimum Bid Price Rule by February 8, 2016. The NASDAQ determination to grant the second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The NASDAQ Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. At-the-Market Program Subsequent to December 31, 2015, the Company sold approximately 50,000 shares of its common stock under the March 2013 Sales Agreement through an “at the market” equity offering program for net proceeds of approximately $17,500. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, funding of the Company’s clinical trials, commercialization of our products, obtaining regulatory approvals, capital expenditures and working capital. As of March 18, 2016, the Company has approximately $39.9 million remaining under the program. As a result of the sales, the exercise price of the February 2015, July 2015 Series A and Series B Warrants has been adjusted to $0.355. July 2015 Series B Warrant Exercises and Expirations The July 2015 Series B Warrants (“Series B Warrants”) expired on January 29, 2016. Prior to expiration, 2.2 million Series B Warrants were exercised for proceeds of approximately $0.8 million. The remaining 7.1 million Series B Warrants expired.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.
Cash Equivalents and Concentrations of Credit Risk	Cash Equivalents and Concentrations of Credit Risk The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.
Accounts Receivable	Accounts Receivable Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified.
Inventories	Inventories Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2015 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.
Derivative Instrument Liability	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges.
Fair Value Measurements	Fair Value Measurements The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). · Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. · Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. · Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
Revenue Recognition	Revenue Recognition Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred.
Research and Development	Research and Development Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.
Stock Based Compensation	Stock Based Compensation The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant. The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
Income Taxes	Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2015, 2014, and 2013 are as follows: (in thousands, except share data) 2015 2014 2013 Net loss – basic $ (14,704 ) $ (17,381 ) $ (30,324 ) Adjust for gain on warrant derivative liability — — (1,835 ) Net loss - diluted (14,704 ) (17,381 ) (32,159 ) Net loss per share – basic (0.91 ) (1.84 ) (4.81 ) Weighted average shares outstanding – basic 16,161,687 9,452,050 6,300,614 Potentially dilutive warrant exercises — — 268,397 Weighted average shares outstanding – diluted 16,161,687 9,452,050 6,569,011 Net loss per share – diluted (0.91 ) (1.84 ) (5.10 ) For the years ended December 31, 2015, 2014 and 2013, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive. Shares excluded from the computation of diluted EPS: 2015 2014 2013 Stock options 756,051 281,735 252,158 Unvested restricted shares 576,000 29,799 20,347 Warrants 18,059,000 850,138 589,500 Total 19,391,051 1,161,672 862,005
Segment Information	Segment Information The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.
Foreign Currency and Currency Translation	Foreign Currency and Currency Translation Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations. The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.
Recently Adopted Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluation the impact of ASU 2014-09 on its consolidated financial statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company expects to adopt this guidance when effective, and does not anticipate that this guidance will materially impact its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the accounting transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. As of December 31, 2015, the company is not early adopting ASU 2015-17. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact of the pending adoption of ASU 2016-02 on its consolidated financial statements.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Calculation of net loss and number of shares used to compute basic and diluted earnings per share	The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2015, 2014, and 2013 are as follows: (in thousands, except share data) 2015 2014 2013 Net loss – basic $ (14,704 ) $ (17,381 ) $ (30,324 ) Adjust for gain on warrant derivative liability — — (1,835 ) Net loss - diluted (14,704 ) (17,381 ) (32,159 ) Net loss per share – basic (0.91 ) (1.84 ) (4.81 ) Weighted average shares outstanding – basic 16,161,687 9,452,050 6,300,614 Potentially dilutive warrant exercises — — 268,397 Weighted average shares outstanding – diluted 16,161,687 9,452,050 6,569,011 Net loss per share – diluted (0.91 ) (1.84 ) (5.10 )
Shares excluded from the computation of diluted EPS	Shares excluded from the computation of diluted EPS: 2015 2014 2013 Stock options 756,051 281,735 252,158 Unvested restricted shares 576,000 29,799 20,347 Warrants 18,059,000 850,138 589,500 Total 19,391,051 1,161,672 862,005

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of: (in thousands) December 31, 2015 December 31, 2014 Raw materials $ 360 $ 203 Work-in-process 251 63 Finished goods 146 83 Total Inventory $ 757 $ 349

Prepaid Expenses and Other Cu27

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets include the following: (in thousands) December 31, 2015 December 31, 2014 Insurance premiums $ 625 $ 591 Kits for clinical use 162 161 Other 173 222 Total prepaid expenses and other current assets $ 960 $ 974

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Components of property, plant and equipment	Property, plant, and equipment consists of: (in thousands) December 31, 2015 December 31, 2014 Buildings and land $ 556 $ 1,629 Enterprise hardware and software 1,520 1,573 Leaseholds 1,305 361 Equipment 902 1,380 Furniture 355 603 Property, plant and equipment, gross 4,638 5,546 Accumulated depreciation (3,506 ) (3,748 ) Property, plant and equipment, net $ 1,132 $ 1,798

Current Accrued Expenses (Table

Current Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Schedule of current accrued expenses	Current accrued expenses include the following: (in thousands) December 31, 2015 December 31, 2014 Compensation, excluding taxes $ 692 $ 2,187 Professional fees 391 341 Short-term portion of lease restructuring 220 239 Clinical trial expenses 219 124 Other 721 712 Total accrued expenses $ 2,243 $ 3,603

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Schedule of restructuring and related costs	The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2015: (in thousands) Employee Costs Lease Liability Total Liability Reserve balance at December 31, 2014 $ 824 $ 1,282 2,106 Charges 403 — 403 Payments/Utilizations (1,156 ) (243 ) (1,399 ) Reserve balance at December 31, 2015 $ 71 $ 1,039 1,110

Assets and Liabilities Measur31

Assets and Liabilities Measured at Fair Value (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of fair value of the warrants	The fair value of the Warrants at December 31, 2015 was determined by using option pricing models assuming the following: Series A 2015 Warrants Series B 2015 Warrants February 2015 Warrants October 2013 Warrants Expected volatility 92.13% 94.03% 92.91% 97.76% Risk free interest rates 1.65% 0.14% 1.54% 1.25% Expected life (in years) 4.56 0.08 4.13 2.83
Assets and liabilities measured at fair value on a recurring basis	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and 2014, aggregated by the level in the fair value hierarchy within which those measurements fall. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Level 2 Level 3 Balance at December 31 (in thousands) 2015 2014 2015 2014 2015 2014 2015 2014 Assets Money market funds (included in Cash and Cash Equivalents) $ 1,943 $ 1,943 $ — $ — $ — $ — $ 1,943 $ 1,943 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 3,785 $ 225 $ 3,785 $ 225
Fair value measurements using significant unobservable inputs	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at January 1, 2013 $ 3,427 Total change in the liability included in earnings (2,756 ) Fair value of warrants issued 1,857 Fair value of warrants exercised (218 ) Balance at December 31, 2013 2,310 Total change in the liability included in earnings (1,942 ) Fair value of warrants exercised (143 ) Balance at December 31, 2014 225 Total change in the liability included in earnings (564 ) Fair value of warrants issued 4,247 Fair value of warrants exercised (123 ) Balance at December 31, 2015 $ 3,785

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
Stock option activity	Stock option activity for 2015, 2014, and 2013 is as follows: Stock Option Activity under the Plans Stock Options Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2012 299,242 $19.68 - 248.64 $ 76.66 6.88 Granted 130,328 4.80 - 34.08 17.41 Forfeited (160,538 ) 19.68 - 29.92 24.47 Expired (16,874 ) 6.08 - 197.44 63.50 Outstanding at December 31, 2013 252,158 $4.80 - 248.64 $ 57.90 7.36 Granted 165,000 1.24 - 2.42 1.78 Forfeited (89,757 ) 4.80 - 248.64 67.58 Expired (45,666 ) 4.80 - 110.40 47.54 Outstanding at December 31, 2014 281,735 $1.24 - $245.12 $ 23.63 8.83 Granted 524,250 1.19 1.19 Forfeited (49,934 ) 1.19 - 169.60 30.01 Outstanding at December 31, 2015 756,051 $1.24 - $245.12 $ 7.65 8.95 Exercisable at December 31, 2015 188,249 $1.24 - $245.12 $ 26.45 7.67
Assumptions used to determine estimated fair value of stock options granted	The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the years ended December 31, 2015, 2014 and 2013: Year ended December 31, 2015 2014 2013 Weighted average risk-free interest rates 1.82 % 1.53 % 1.30 % Weighted average expected volatility 97.70 % 96.68 % 92.31 % Expected volatility 97.70 % 95.47% - 98.14% 86.16% - 97.21% Dividend yield — — — Weighted average expected option term (in years) 5.15 4.50 5.66 Weighted average grant date fair value $ 0.89 $ 1.78 $ 17.41
Summary of non-vested options	A summary of the Company’s non-vested options to purchase shares as of December 31, 2015 and changes during the year ended December 31, 2015 and December 31, 2014 are presented below: Non-Vested Options Number of Options Weighted Average Exercise Price Non-vested at January 1, 2014 118,610 $ 20.76 Granted 165,000 1.78 Vested (46,737 ) 26.35 Forfeited (10,772 ) 35.92 Non-vested at December 31, 2014 226,101 $ 5.03 Granted 524,250 1.19 Vested (159,901 ) 5.36 Forfeited (22,648 ) 4.38 Non-vested at December 31, 2015 567,802 $ 1.42
Summary of restricted stock activity	A summary of the Company’s restricted stock activity as of December 31, 2015 and changes during the year ended December 31, 2015 and December 31, 2014 are presented below: Restricted Stock Activity Number of Shares Weighted Average Grant Date Fair Value Non-vested at January 1, 2014 20,347 $ 16.84 Granted 62,504 2.60 Vested (18,815 ) 13.60 Forfeited (34,237 ) 3.40 Non-vested at December 31, 2014 29,799 $ 4.46 Granted 576,000 1.19 Vested (29,666 ) 4.38 Forfeited (133 ) 21.58 Non-vested at December 31, 2015 576,000 $ 1.19
Summary of warrant activity	A summary of warrant activity is as follows: Warrants Exercise per Share Weighted Average Exercise Price Weighted Average Remaining Life (Years) Outstanding at January 1, 2013 352,664 $ 19.20 $ 19.20 2.24 Issued 589,500 7.04 Exercised (12,669 ) 19.20 Expired — — Outstanding at December 31, 2013 929,495 $2.56 – 7.04 $ 5.40 3.51 Issued — — Exercised (49,139 ) 2.56 Expired (30,218 ) 2.56 Outstanding at December 31, 2014 850,138 $1.75 – 7.04 $ 5.42 2.78 Issued 17,469,500 0.80 Exercised (215,318 ) 0.82 Expired (45,320 ) 0.82 Outstanding at December 31, 2015 18,059,000 $0.74 – 7.04 $ 1.00 2.16

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments, net of receipts due under terms of subleases under all operating leases	Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2015 are as follows: (in thousands) Future Payment 2016 $ 505 2017 455 2018 460 2019 442 2020 435 2021 175 $ 2,472

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income Before Income Taxes	Income before income taxes consists of: Year Ended December 31, (in thousands) 2015 2014 2013 Domestic $ (11,276 ) $ (12,950 ) $ (19,142 ) Foreign (3,428 ) (4,431 ) (11,182 ) Income before taxes $ (14,704 ) $ (17,381 ) $ (30,324 )
Income tax reconciliation	The provision for income taxes differs from the amount computed by applying the statutory rate as follows: Year Ended December 31, (in thousands) 2015 2014 2013 Income taxes using U.S federal statutory rate $ (4,999 ) $ (5,926 ) $ (10,309 ) Amortization of gain on IP migration 767 767 781 State income taxes, net of federal benefit 380 2,215 (1,390 ) Foreign rate differential 920 1,069 2,761 Valuation allowance 2,649 886 7,683 Derivative charge (192 ) (660 ) (937 ) Stock option exercises and cancellations 674 1,748 1,589 Research and development costs (199 ) (125 ) (1,090 ) Other — 26 912 $ — $ — $ —
Significant components of deferred tax assets	Significant components of the Company’s deferred tax assets are as follows: (in thousands) December 31, 2015 December 31, 2014 Deferred tax assets: Employee compensation accruals $ 1,279 $ 1,866 Accrued liabilities 633 1,356 Research tax credits 3,796 3,597 Other 66 45 Net operating losses 77,906 74,359 Total deferred tax assets 83,680 81,223 Deferred tax liabilities: Total deferred tax liabilities — — Valuation allowance 83,680 81,223 Net deferred tax assets $ — $ —

Quarterly Financial Data (Una35

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly financial data	Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2015 and 2014. 2015 Quarters Ended (in thousands except per share amounts) March 31 June 30 September December 31 Operating loss $ (3,708 ) (3,623 ) (3,650 ) (4,229 ) Change in fair value of warrant liability, net 209 (48 ) 1,253 (850 ) Net loss (3,488 ) (3,699 ) (2,422 ) (5,095 ) Basic and diluted loss per share (0.32 ) (0.30 ) (0.12 ) (0.23 ) 2014 Quarters Ended (in thousands except per share amounts) March 31 June 30 September December 31 Operating loss $ (5,059 ) (5,904 ) (5,054 ) (3,285 ) Change in fair value of warrant liability, net (205 ) 1,297 519 330 Net loss (5,278 ) (4,600 ) (4,558 ) (2,945 ) Basic loss per share (0.57 ) (0.49 ) (0.48 ) (0.31 ) Diluted loss per share (0.57 ) (0.52 ) (0.48 ) (0.31 )

Description of Business and L36

Description of Business and Liquidity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Description Of Business And Liquidity [Abstract]
Net loss	$ (5,095)	$ (2,422)	$ (3,699)	$ (3,488)	$ (2,945)	$ (4,558)	$ (4,600)	$ (5,278)	$ (14,704)	$ (17,381)	$ (30,324)
Net cash used in operating activities									(16,420)	(15,552)	$ (34,102)
Accumulated deficit	$ (261,217)				$ (246,513)				$ (261,217)	$ (246,513)

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2015Segment
Summary Of Significant Accounting Policies [Line Items]
Maximum number of months of investments with original maturities from date of acquisition to be cash equivalents	3 months
Number of business segments	1
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	7 years

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Calculation of net loss and the number of shares used to compute basic and diluted earnings per share [Abstract]
Net loss – basic		$ (5,095)	$ (2,422)	$ (3,699)	$ (3,488)	$ (2,945)	$ (4,558)	$ (4,600)	$ (5,278)	$ (14,704)		$ (17,381)		$ (30,324)
Adjust for gain on warrant derivative liability														(1,835)
Net loss - diluted										$ (14,704)		$ (17,381)		$ (32,159)
Net loss per share – basic						$ (0.31)	$ (0.48)	$ (0.49)	$ (0.57)	$ (0.91)	[1]	$ (1.84)	[1]	$ (4.81)	[1]
Weighted average shares outstanding – basic	[1]									16,161,687		9,452,050		6,300,614
Potentially dilutive warrant exercises														268,397
Weighted average shares outstanding – diluted	[1]									16,161,687		9,452,050		6,569,011
Net loss per share – diluted						$ (0.31)	$ (0.48)	$ (0.52)	$ (0.57)	$ (0.91)	[1]	$ (1.84)	[1]	$ (5.10)	[1]
[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Summary of Shares Excluded from the Computation of Diluted EPS (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	19,391,051	1,161,672	862,005
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	756,051	281,735	252,158
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	576,000	29,799	20,347
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	18,059,000	850,138	589,500

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 360	$ 203
Work-in-process	251	63
Finished goods	146	83
Total Inventory	$ 757	$ 349

Prepaid Expenses and Other Cu41

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 625	$ 591
Kits for clinical use	162	161
Other	173	222
Total prepaid expenses and other current assets	$ 960	$ 974

Prepaid Expenses and Other Cu42

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipmen43

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 4,638	$ 5,546
Accumulated depreciation	(3,506)	(3,748)
Property, plant and equipment, net	1,132	1,798
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	556	1,629
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,520	1,573
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,305	361
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	902	1,380
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 355	$ 603

Property, Plant, and Equipmen44

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Abstract]
Depreciation expense	$ 617	$ 958	$ 1,126

Current Accrued Expenses - Sche

Current Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Compensation, excluding taxes	$ 692	$ 2,187
Professional fees	391	341
Short-term portion of lease restructuring	220	239
Clinical trial expenses	219	124
Other	721	712
Total accrued expenses	$ 2,243	$ 3,603

Current Accrued Expenses - Addi

Current Accrued Expenses - Additional Information (Details)	Dec. 31, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Restructuring Expenses - Additi

Restructuring Expenses - Additional Information (Details) $ in Thousands	Aug. 18, 2014USD ($)	May. 22, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2013USD ($)Employee	Dec. 31, 2014USD ($)
Restructuring Cost And Reserve [Line Items]
Severance costs				$ 5,500
Restructuring reserve balance			$ 1,110		$ 2,106
Restructuring reserve charges			403
Sub-lease 1 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			1,039		$ 1,282
Other non-current liabilities [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			800
Accrued Expenses [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			100
Accrued Expenses [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 200
Operating Expense [Member]
Restructuring Cost And Reserve [Line Items]
Number of positions eliminated | Employee				59

Restructuring Expenses - Schedu

Restructuring Expenses - Schedule of Restructuring and Related Costs(Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 2,106
Charges	403
Payments/Utilizations	(1,399)
Restructuring reserve balance	1,110
Employee Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	824
Charges	403
Payments/Utilizations	(1,156)
Restructuring reserve balance	71
Lease Liability [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	1,282
Payments/Utilizations	(243)
Restructuring reserve balance	$ 1,039

Assets and Liabilities Measur49

Assets and Liabilities Measured at Fair Value - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended								12 Months Ended
	Jul. 31, 2015USD ($)shares	Feb. 28, 2015USD ($)shares	Oct. 31, 2013USD ($)shares	May. 31, 2012USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)shares	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)Input$ / sharesshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)shares	Apr. 30, 2014$ / shares	Dec. 31, 2012$ / sharesshares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of inputs used for valuation of warrants | Input													6
Sale of units to underwriter	9,400,000
Common stock sold through the program (in shares)	9,400,000	2,500,000	1,300,000	1,000,000											0
Proceeds From Issuance Of Common Stock | $	$ 6,000
Exercise price of Warrants (in dollars per share) | $ / shares																	$ 19.20
Warrant outstanding					18,059,000				850,138				18,059,000	850,138	929,495		352,664
Proceeds from issuance of private placement | $		$ 2,600	$ 7,500	$ 21,500
Net proceeds from issuance of private placement | $		2,500	6,900	21,100
Derivative warrant liability [Abstract]
Change in fair value of the warrant liability, net | $					$ 850	$ (1,253)	$ 48	$ (209)	$ (330)	$ (519)	$ (1,297)	$ 205	$ 564	$ 1,942	$ 2,756
Derivative warrant liabilities | $					$ 3,785				$ 225				$ 3,785	$ 225
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Value of warrants issued | $		$ 800
Exercise price of Warrants (in dollars per share) | $ / shares					$ 0.74								$ 0.74
Warrant outstanding					1,100,000								1,100,000
Number of warrants exercised													0
Warrants issued (in shares)		1,100,000
Proceeds from issuance of private placement | $		$ 2,600
Net proceeds from issuance of private placement | $		$ 2,500
Term period for warrants													5 years
Series A Common Stock Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Term period for warrants													5 years
2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Value of warrants issued | $			$ 1,900
Exercise price of Warrants (in dollars per share) | $ / shares					$ 7.04								$ 7.04			$ 7.04
Warrant outstanding					600,000								600,000
Number of warrants exercised													0
Warrants issued (in shares)			600,000
Term period for warrants													5 years
2012 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Value of warrants issued | $				$ 3,400
Warrants expiration date													May 31, 2015
Warrants issued (in shares)				300,000
Term period for warrants													3 years
Warrants Exercised (in shares)													200,000
Net proceeds from exercise of warrants | $													$ 200
Series A Common Stock Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of warrants converted	7,000,000
Gross Proceeds From Underwriting Offering | $	$ 7,000
Exercise price of Warrants (in dollars per share) | $ / shares					$ 0.87								$ 0.87
Warrant outstanding					7,000,000								7,000,000
Warrants expiry period													5 years
Series B Common Stock Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of warrants converted	9,400,000
Exercise price of Warrants (in dollars per share) | $ / shares					$ 0.75								$ 0.75
Warrant outstanding					9,400,000								9,400,000
Warrants expiration date													Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Value of warrants issued | $	$ 3,400
Number of warrants exercised													0

Assets and Liabilities Measur50

Assets and Liabilities Measured at Fair Value - Schedule of Fair Value of Warrants (Details)	12 Months Ended
	Dec. 31, 2015
Series A 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	92.13%
Risk free interest rates (in hundredths)	1.65%
Expected life (in years)	4 years 6 months 22 days
Series B 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	94.03%
Risk free interest rates (in hundredths)	0.14%
Expected life (in years)	29 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	92.91%
Risk free interest rates (in hundredths)	1.54%
Expected life (in years)	4 years 1 month 17 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	97.76%
Risk free interest rates (in hundredths)	1.25%
Expected life (in years)	2 years 9 months 29 days

Assets and Liabilities Measur51

Assets and Liabilities Measured at Fair Value - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Derivative Instruments Liabilities [Member]
Liabilities [Abstract]
Total Liabilities	$ 3,785	$ 225
Level 3 [Member] | Derivative Instruments Liabilities [Member]
Liabilities [Abstract]
Total Liabilities	3,785	225
Money Market Funds [Member]
Assets [Abstract]
Total Assets	1,943	1,943
Money Market Funds [Member] | Level 1 [Member]
Assets [Abstract]
Total Assets	$ 1,943	$ 1,943

Assets and Liabilities Measur52

Assets and Liabilities Measured at Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 225	$ 2,310	$ 3,427
Total change in the fair value of the liability included in earnings	(564)	(1,942)	(2,756)
Fair value of warrants issued	4,247	0	1,857
Fair value of warrants exercised	(123)	(143)	(218)
Ending balance	$ 3,785	$ 225	$ 2,310

Stockholders' Equity - Reverse

Stockholders' Equity - Reverse Stock Split - Additional Information (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares
Stockholders Equity Note [Abstract]
Reverse stock split ratio	0.0625
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Number of fractional shares were issued in connection with the reverse stock split	0

Stockholders' Equity - Stock Is

Stockholders' Equity - Stock Issuances - Additional Information (Details) - USD ($)	1 Months Ended				12 Months Ended
	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	May. 31, 2012	Dec. 31, 2015	Dec. 31, 2013	Oct. 20, 2015	Dec. 31, 2014	Apr. 30, 2014	Mar. 31, 2013	Dec. 31, 2012
Stockholders Equity Note [Line Items]
Sale of units to underwriter	9,400,000
Sale of common stock, net of expenses (in shares)	9,400,000	2,500,000	1,300,000	1,000,000		0
Proceeds of common stock issued, net of related expenses	$ 6,000,000
Warrants exercisable per share price (in dollars per share)											$ 19.20
Number of warrants outstanding (in shares)					18,059,000	929,495		850,138			352,664
Proceeds from issuance of private placement		$ 2,600,000	$ 7,500,000	$ 21,500,000
Net proceeds from issuance of private placement		2,500,000	6,900,000	$ 21,100,000
Securities available subject to market conditions					$ 77,400,000
Common stock, par value (in dollars per share)					$ 0.01			$ 0.01
Proceeds from issuance of common stock	$ 6,000,000
ATM Programs [Member] | Cowen and Company, LLC [Member]
Stockholders Equity Note [Line Items]
Sale of common stock, net of expenses (in shares)					1,000,000	1,000,000
Proceeds of common stock issued, net of related expenses					$ 4,700,000	$ 4,800,000
Common stock, par value (in dollars per share)										$ 0.01
Aggregate proceeds from sale of common stock under equity offering program, maximum										$ 50,000,000
Proceeds from issuance of common stock					4,800,000	$ 5,000,000
Aggregate proceeds from sale of common stock under equity offering program, remaining					$ 39,900,000
Maximum [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share)					$ 7.04	$ 7.04		$ 7.04
Maximum offering and selling of stock and securities that entity make to raise capital							$ 77,400,000
Entity public float pursuant to SEC regulations							$ 75,000,000
February 2015 Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued		$ 800,000
Warrants exercisable per share price (in dollars per share)					$ 0.74
Number of warrants outstanding (in shares)					1,100,000
Warrants issued (in shares)		1,100,000
Proceeds from issuance of private placement		$ 2,600,000
Net proceeds from issuance of private placement		$ 2,500,000
Term period for warrants					5 years
2013 Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued			$ 1,900,000
Warrants exercisable per share price (in dollars per share)					$ 7.04				$ 7.04
Number of warrants outstanding (in shares)					600,000
Warrants issued (in shares)			600,000
Term period for warrants					5 years
Series A Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Number of warrants converted	7,000,000
Gross Proceeds From Underwriting Offering	$ 7,000,000
Warrants exercisable per share price (in dollars per share)					$ 0.87
Number of warrants outstanding (in shares)					7,000,000
Series B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Number of warrants converted	9,400,000
Warrants exercisable per share price (in dollars per share)					$ 0.75
Number of warrants outstanding (in shares)					9,400,000
Warrants expiration date					Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued	$ 3,400,000

Stockholders' Equity - Stock In

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 349,000	$ 391,000	$ 174,000
Additional compensation expense relating to stock options		200,000
Restricted stock compensation expense		308,000	100,000	117,000
Additional compensation expense relating to restricted stock		400,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 300,000	400,000	200,000
Remaining average recognition period for unrecognized compensation expense		1 year 1 month 21 days
Aggregate intrinsic value of options outstanding and exercisable		$ 0
Closing stock price (in dollars per share)		$ 0.50
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining average recognition period for unrecognized compensation expense		1 year 5 months 12 days
Restricted stock compensation expense		$ 300,000	$ 100,000	$ 100,000
2004 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		187,500
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	406,250	1,506,250
Increased number of shares (in shares)	1,100,000
Shares available for grant		185,450

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options, Number of Options [Roll Forward]
Outstanding, beginning of period (in shares)	281,735	252,158	299,242
Granted (in shares)	524,250	165,000	130,328
Forfeited (in shares)	(49,934)	(89,757)	(160,538)
Expired (in shares)		(45,666)	(16,874)
Outstanding, end of period (in shares)	756,051	281,735	252,158	299,242
Exercisable (in shares)	188,249
Stock Options, Exercise Price per Share [Roll Forward]
Granted (in dollars per share)	$ 1.19
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	23.63	$ 57.90	$ 76.66
Granted (in dollars per share)	1.19	1.78	17.41
Forfeited (in dollars per share)	30.01	67.58	24.47
Expired (in dollars per share)		47.54	63.50
Outstanding, beginning of period (in dollars per share)	7.65	$ 23.63	$ 57.90	$ 76.66
Exercisable (in dollars per share)	$ 26.45
Stock Options, Weighted Average Remaining Life Years [Abstract]
Outstanding	8 years 11 months 12 days	8 years 9 months 29 days	7 years 4 months 10 days	6 years 10 months 17 days
Exercisable	7 years 8 months 1 day
Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 1.24	$ 4.80	$ 19.68
Granted (in dollars per share)		1.24	4.80
Forfeited (in dollars per share)	1.19	4.80	19.68
Expired (in dollars per share)		4.80	6.08
Outstanding, end of period (in dollars per share)	1.24	1.24	4.80	$ 19.68
Exercisable (in dollars per share)	1.24
Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	245.12	248.64	248.64
Granted (in dollars per share)		2.42	34.08
Forfeited (in dollars per share)	169.60	248.64	29.92
Expired (in dollars per share)		110.40	197.44
Outstanding, end of period (in dollars per share)	245.12	$ 245.12	$ 248.64	$ 248.64
Exercisable (in dollars per share)	$ 245.12

Stockholders' Equity - Assumpti

Stockholders' Equity - Assumptions Used to Determine Estimated Fair Value of Stock Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average grant date fair value (in dollars per share)	$ 1.19	$ 1.78
Stock Options [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average risk-free interest rates (in hundredths)	1.82%	1.53%	1.30%
Weighted average expected volatility (in hundredths)	97.70%	96.68%	92.31%
Expected volatility (in hundredths)	97.70%
Weighted average expected option term (in years)	5 years 1 month 24 days	4 years 6 months	5 years 7 months 28 days
Weighted average grant date fair value (in dollars per share)	$ 0.89	$ 1.78	$ 17.41
Stock Options [Member] | Minimum [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)		95.47%	86.16%
Stock Options [Member] | Maximum [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)		98.14%	97.21%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Non-vested Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Non-vested Options, Number of Options [Roll Forward]
Non-vested, beginning of period (in shares)	226,101	118,610
Granted (in shares)	524,250	165,000	130,328
Vested (in shares)	(159,901)	(46,737)
Forfeited (in shares)	(22,648)	(10,772)
Non-vested, end of period (in shares)	567,802	226,101	118,610
Non-vested Options, Weighted Average Exercise Price [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 5.03	$ 20.76
Granted (in dollars per share)	1.19	1.78
Vested (in dollars per share)	5.36	26.35
Forfeited (in dollars per share)	4.38	35.92
Non-vested, end of period (in dollars per share)	$ 1.42	$ 5.03	$ 20.76

Stockholders' Equity - Summar59

Stockholders' Equity - Summary of Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Restricted Stock, Number of Shares [Roll Forward]
Outstanding, beginning of period (in shares)	29,799	20,347
Granted (in shares)	576,000	62,504
Vested (in shares)	(29,666)	(18,815)
Forfeited (in shares)	(133)	(34,237)
Outstanding, end of period (in shares)	576,000	29,799
Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 4.46	$ 16.84
Granted (in dollars per share)	1.19	2.60
Vested (in dollars per share)	4.38	13.60
Forfeited (in dollars per share)	21.58	3.40
Non-vested, end of period (in dollars per share)	$ 1.19	$ 4.46

Stockholders' Equity - Summar60

Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	850,138	929,495	352,664
Issued (in shares)	17,469,500		589,500
Exercised (in shares)	(215,318)	(49,139)	(12,669)
Expired (in shares)	(45,320)	(30,218)
Outstanding, end of period (in shares)	18,059,000	850,138	929,495	352,664
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)				$ 19.20
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 5.42	$ 5.40	$ 19.20
Issued (in dollars per share)	0.80		7.04
Exercised (in dollars per share)	0.82	2.56	19.20
Expired (in dollars per share)	0.82	2.56
Outstanding, end of period (in dollars per share)	$ 1	$ 5.42	$ 5.40	$ 19.20
Weighted average remaining life	2 years 1 month 28 days	2 years 9 months 11 days	3 years 6 months 4 days	2 years 2 months 27 days
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 0.74	$ 1.75	$ 2.56
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 7.04	$ 7.04	$ 7.04

Loan and Security Agreement (De

Loan and Security Agreement (Details) - Silicon Valley Bank [Member]	12 Months Ended
	Dec. 31, 2015USD ($)
Line Of Credit Facility [Line Items]
Loan and security agreement	4 years
Credit agreement, revolving credit facility	$ 20,000,000
Line of credit facility, covenant terms	In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB.
Cash and cash equivalents	$ 15,000,000

Commitments Additional Informat

Commitments Additional Information (Details)	12 Months Ended
	Dec. 31, 2015USD ($)ft²	Dec. 31, 2015EUR (€)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Operating Leased Assets [Line Items]
Rent expense	$ 400,000		$ 2,300,000	$ 1,500,000
Rent expense related to restructuring charges	$ 1,300,000
Office Space at 810 Seventh Avenue, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	8,629
Expansion option, additional square footage of office space (in square feet) | ft²	8,629
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement	$ 881,297
Expiration date of letter of credit	Feb. 1, 2017	Feb. 1, 2017
Office Space in New York, NY, Lease Amendment [Member]
Operating Leased Assets [Line Items]
Additional square footage of office space leased under exercise of option right (in square feet) | ft²	8,629
Lease expiration date	Mar. 31, 2021	Mar. 31, 2021
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 1 [Member]
Operating Leased Assets [Line Items]
Annual base rent	$ 961,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 2 [Member]
Operating Leased Assets [Line Items]
Annual base rent	970,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 3 [Member]
Operating Leased Assets [Line Items]
Annual base rent	996,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent	996,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent	1,000,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Years Thereafter [Member]
Operating Leased Assets [Line Items]
Annual base rent	$ 1,100,000
Delcath's European Headquarters Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	19,200
Operating lease term	10 years	10 years
Delivery time frame of written notice, minimum	6 months	6 months
Delcath's European Headquarters Lease Agreement [Member] | Year 1 [Member]
Operating Leased Assets [Line Items]
Annual base rent	$ 115,458	€ 106,051
Delcath's European Headquarters Lease Agreement [Member] | Year 2 [Member]
Operating Leased Assets [Line Items]
Annual base rent	146,946	134,974
Delcath's European Headquarters Lease Agreement [Member] | Year 3 [Member]
Operating Leased Assets [Line Items]
Annual base rent	173,187	159,077
Delcath's European Headquarters Lease Agreement [Member] | Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent	199,427	183,179
Delcath's European Headquarters Lease Agreement [Member] | Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent	$ 199,427	€ 183,179
Country Club Road Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	18,000
Annual base rent	$ 216,000
Operating lease term	3 years	3 years
Lease expiration period	2015-06	2015-06
Office Space at 1301 Avenue of the Americas, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	5,818
Annual base rent	$ 200,000
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement	$ 200,000
Expiration date of letter of credit	May 1, 2016	May 1, 2016
Park Road Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	6,000
Lease expiration date	Oct. 31, 2016	Oct. 31, 2016
Annual base rent	$ 47,277
Operating lease term	1 year	1 year

Commitments - Schedule Future M

Commitments - Schedule Future Minimum Lease Payments, Net of Receipts Due Under Terms of Subleases Under All Operating Leases (Details) $ in Thousands	Dec. 31, 2015USD ($)
Future minimum lease payments under all operating leases [Abstract]
2,016	$ 505
2,017	455
2,018	460
2,019	442
2,020	435
2,021	175
Total future minimum payments due	$ 2,472

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Income tax provision	$ 0	$ 0	$ 0
Percentage of valuation allowance against deferred tax assets	100.00%
Valuation allowance	$ 2,649,000	886,000	$ 7,683,000
Tax benefit related to the exercise of non qualified stock options	1,000,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	184,500,000	171,600,000
Operating loss carryforwards, amount subject to limitations	8,600,000
Operating loss carryforwards, annual limitation	123,000
Operating loss carryforwards, net of limitations	$ 175,900,000
State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	2,035
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 22,100,000	21,800,000
Federal Research and Development Tax Credit Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 3,800,000	3,600,000
Tax credit carryforwards, expiration dates	2,035
Minimum [Member] | State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 27,300,000	110,500,000
Maximum [Member] | State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 109,700,000	$ 276,300,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments [Abstract]
Domestic	$ (11,276)	$ (12,950)	$ (19,142)
Foreign	(3,428)	(4,431)	(11,182)
Income before taxes	$ (14,704)	$ (17,381)	$ (30,324)

Income Taxes - Income tax recon

Income Taxes - Income tax reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Provision for income taxes [Abstract]
Income taxes using U.S federal statutory rate	$ (4,999,000)	$ (5,926,000)	$ (10,309,000)
Amortization of gain on IP migration	767,000	767,000	781,000
State income taxes, net of federal benefit	380,000	2,215,000	(1,390,000)
Foreign rate differential	920,000	1,069,000	2,761,000
Valuation allowance	2,649,000	886,000	7,683,000
Derivative charge	(192,000)	(660,000)	(937,000)
Stock option exercises and cancellations	674,000	1,748,000	1,589,000
Research and development costs	(199,000)	(125,000)	(1,090,000)
Other		26,000	912,000
Total	$ 0	$ 0	$ 0

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Employee compensation accruals	$ 1,279	$ 1,866
Accrued liabilities	633	1,356
Research tax credits	3,796	3,597
Other	66	45
Net operating losses	77,906	74,359
Total deferred tax assets	83,680	81,223
Deferred tax liabilities:
Total deferred tax liabilities	0	0
Valuation allowance	83,680	81,223
Net deferred tax assets	$ 0	$ 0

Quarterly Financial Data (Una68

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Operating loss	$ (4,229)	$ (3,650)	$ (3,623)	$ (3,708)	$ (3,285)	$ (5,054)	$ (5,904)	$ (5,059)	$ (15,210)		$ (19,304)		$ (33,019)
Change in fair value of warrant liability, net	(850)	1,253	(48)	209	330	519	1,297	(205)	(564)		(1,942)		(2,756)
Net loss	$ (5,095)	$ (2,422)	$ (3,699)	$ (3,488)	$ (2,945)	$ (4,558)	$ (4,600)	$ (5,278)	$ (14,704)		$ (17,381)		$ (30,324)
Basic and diluted loss per share	$ (0.23)	$ (0.12)	$ (0.30)	$ (0.32)
Basic loss per share					$ (0.31)	$ (0.48)	$ (0.49)	$ (0.57)	$ (0.91)	[1]	$ (1.84)	[1]	$ (4.81)	[1]
Diluted loss per share					$ (0.31)	$ (0.48)	$ (0.52)	$ (0.57)	$ (0.91)	[1]	$ (1.84)	[1]	$ (5.10)	[1]
[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Aug. 08, 2016	Feb. 09, 2016	Aug. 11, 2015	Jan. 29, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	May. 31, 2012	Dec. 31, 2013	Mar. 17, 2016
Subsequent Event [Line Items]
Minimum bid price per share required to regain compliance with listing qualifications			$ 1
Stock market granted consecutive trading days preceding the date of notice			30 days
Common stock sold through the program (in shares)					9,400,000	2,500,000	1,300,000	1,000,000	0
Net proceeds from issuance of common stock					$ 6,000,000
ATM Programs [Member] | Series A and B Common Stock Warrants [Member]
Subsequent Event [Line Items]
Adjusted exercise price of Warrants (in dollars per share)					$ 0.355	$ 0.355
Subsequent Event [Member]
Subsequent Event [Line Items]
Minimum bid price per share required to regain compliance with listing qualifications		$ 1
Stock market granted additional calendar days	180 days
Subsequent Event [Member] | Series B Common Stock Warrants [Member]
Subsequent Event [Line Items]
Warrants Exercised (in shares)				2,200,000
Net proceeds from exercise of warrants				$ 800,000
Remaining outstanding warrants expired				7,100,000
Subsequent Event [Member] | ATM Programs [Member]
Subsequent Event [Line Items]
Common stock sold through the program (in shares)		50,000
Net proceeds from issuance of common stock		$ 17,500
Aggregate proceeds from sale of common stock under equity offering program, remaining										$ 39,900,000